Logo

Asuragen Raises $18.5M in Series B Financing

Dec 11, 2007
NEW YORK (GenomeWeb News) – Asuragen said yesterday that it has raised $18.5 million in Series B financing.
 
The funding adds to $49 million that the company raised in a Series A round last year.
 
Investors in the Series B round include PTV Sciences, a new investor, as well as previous investors Telegraph Hill Partners and Growth Capital Partners.
 
Asuragen is a spinoff of Ambion that was formed after Applied Biosystems acquired Ambion's RNA business in March 2006. It includes Ambion's former diagnostics and services division as well as a discovery group.
 
In addition to diagnostic research, Asuragen is developing microRNAs as cancer therapeutics and is conducting pre-clinical development of its lead candidates.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.